Triple-negative breast cancer: Molecular characteristics and potential therapeutic approaches;Potrójnie negatywny rak piersi: Molekularna charakterystyka i potencjalne strategie terapeutyczne

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 1090-1097

  Nowacka Zawisza, Maria ^a   Krajewska, Wanda Małgorzata ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Anticancer therapy; BRCA1 2; Epidermal growth factor receptor HER2; Estrogen receptors; Progesterone receptor; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BRAP PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN RECEPTOR;

ANIMAL; ARTICLE; DRUG ANTAGONISM; GENETICS; HUMAN; MUTATION; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; HEDGEHOG PROTEINS; HUMANS; MUTATION; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84892615839     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1077713     Document Type: Article

References (46)

1. Atchley D. P., Albarracin C. T., Lopez A., Valero V., Amos C. I., Gonzalez-Angulo A. M., Hortobagyi G. N., Arun B. K.: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol., 2008;26:4282-4288
2. Bauer K. R., Brown M., Cress R. D., Parise C. A., Caggiano V.: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer, 2007;109:1721-1728
3. Bertucci F., Finetti P., Cervera N., Charafe-Jauffret E., Buttarelli M., Jacquemier J., Chaffanet M., Maraninchi D., Viens P., Birnbaum D.: How different are luminal A and basal breast cancers? Int. J. Cancer, 2009;124:1338-1348
4. Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., Viens P., Birnbaum D.: How basal are triple-negative breast cancers? Int. J. Cancer, 2008;123:236-240
5. Chacón R. D., Costanzo M. V.: Triple-negative breast cancer. Breast Cancer Res., 2010;12(Suppl. 2):S3
6. Cleator S., Heller W., Coombes R. C.: Triple-negative breast cancer: therapeutic options. Lancet Oncol., 2007;8:235-244
7. Dawson S. J., Provenzano E., Caldas C.: Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer, 2009;45(Suppl. 1):27-40
8. de Ruijter T. C., Veeck J., de Hoon J. P., van Engeland M., Tjan-Heijnen V. C.: Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol., 2011;137:183-192
9. Dȩbska S., Kubicka J., Czyżykowski R., Habib M., Potemski P.: Inhibitory PARP-podstawy teoretyczne i zastosowanie kliniczne. Postȩpy Hig. Med. Dośw., 2012;66:311-321
10. Domagała P., Huzarski T., Lubiński J., Gugala K., Domagała W.: PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res. Treat., 2011;127:861-869
11. Duchnowska R.: Leczenie celowane-nowe nadzieje w leczeniu raka piersi. Onkol. Prakt. Klin., 2007;3:128-134
12. Duchnowska R.:, Podpis genowy" jako czynnik rokowniczy w uzupełniaja̧cym leczeniu raka piersi. Onkol. Prak. Klin., 2009;5:237-243
13. Duda-Szymańska J., Sporny S.: Praktyczna wartość molekularnej klasyfikacji raków sutka. Pol. Merkur. Lekarski, 2011;31:5-8
14. Fang L., Barekati Z., Zhang B., Liu Z., Zhong X.: Targeted therapy in breast cancer: what's new? Swiss Med. Wkly., 2011;141:w13231
15. Finn R. S., Dering J., Ginther C., Wilson C. A., Glaspy P., Tchekmedyian N., Slamon D. J.: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro. Breast Cancer Res. Treat., 2007;105:319-326
16. Foulkes W. D., Smith I. E., Reis-Filho J. S.: Triple-negative breast cancer. N. Engl. J. Med., 2010;363:1938-1948
17. Gao W.: Androgen receptor as a therapeutic target. Adv. Drug Deliv. Rev., 2010;62:1277-1284
18. Hammond M. E., Hayes D. F., Dowsett M., Allred D. C., Hagerty K. L., Badve S., Fitzgibbons P. L., Francis G., Goldstein N. S., Hayes M., Hicks D. G., Lester S., Love R., Mangu P. B., McShane L. i wsp.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol., 2010;28:2784-2795
19. Hugh J., Hanson J., Cheang M. C., Nielsen T. O., Perou C. M., Dumontet C., Reed J., Krajewska M., Treilleux I., Rupin M., Magherini E., Mackey J., Martin M., Vogel C.: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol., 2009;27:1168-1176
20. Kiliańska Z. M., Żołnierczyk J., Wȩsierska- Ga̧dek J.: Biologiczna aktywność polimerazy poli (ADP-rybozy)-1. Postȩpy Hig. Med. Dośw., 2010;64:344-363
21. Kluzek K., Białkowska A., Koczorowska A., Zdzienicka M. Z.: Inhibitory polimerazy poli (ADP-rybozy) (PARP) w terapii nowotworów z mutacjami BRCA1/2. Postȩpy Hig. Med. Dośw., 2012;66:372-384
22. Kordek R., Bednarek A. K.: Mikromacierze DNA w badaniach raka piersi. Onkol. Prakt. Klin., 2005;1:10-17
23. Krześlak A.: Kinaza Akt: kluczowy regulator metabolizmu i progresji nowotworów. Postȩpy Hig. Med. Dośw., 2010;64:490-503
24. Lehmann B. D., Bauer J. A., Chen X., Sanders M. E., Chakravarthy A. B., Shyr Y., Pietenpol J. A.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest., 2011;121:2750-2767
25. Linn S. C., Van't Veer L. J.: Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. Eur. J. Cancer, 2009;45(Suppl. 1):11-26
26. Meyer P., Landgraf K., Högel B., Eiermann W., Ataseven B.: BRCA2 mutations and triple-negative breast cancer. PLoS One, 2012;7:e38361
27. Minami C. A., Chung D. U., Chang H. R.: Management options in triple-negative breast cancer. Breast Cancer, 2011;5:175-199
28. Miyoshi Y., Murase K., Oh K.: Basal-like subtype and BRCA1 dysfunction in breast cancers. Int. J. Clin. Oncol., 2008;13:395-400
29. Niemiec J., Ryś J.: Podtyp podstawny raka piersi-jednostka o specyficznej charakterystyce immunofenotypowej? Pol. J. Pathol., 2009;3(Suppl. 1):s36-s44
30. Niemiec J., Ryś J.: Morfologia i immunocharakterystyka raka piersi w świetle nowych pogla̧dów na temat karcinogenezy. Pol. J. Pathol. (Suppl. 1) s1-s9
31. O'Shaughnessy J., Osborne C., Pippen J. E., Yoffe M., Patt D., Rocha C., Koo I. C., Sherman B. M., Bradley C.: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med., 2011;364:205-214
32. O'Toole S. A., Beith J. M., Millar E. K., West R., McLean A., Cazet A., Swarbrick A., Oakes S. R.: Therapeutic targets in triple negative breast cancer. J. Clin. Pathol., 2013, 66:530-542
33. Pal S. K., Childs B. H., Pegram M.: Triple negative breast cancer: unmet medical needs. Breast Cancer Res. Treat., 2011;125:627-636
34. Pal S. K., Mortimer J.: Triple-negative breast cancer: novel therapies and new directions. Maturitas, 2009;63:269-274
35. Podo F., Buydens L. M., Degani H., Hilhorst R., Klipp E., Gribbestad I. S., Van Huffel S., van Laarhoven H. W., Luts J., Monleon D., Postma G. J., Schneiderhan-Marra N., Santoro F., Wouters H., Russnes H. G. i wsp.: Triple-negative breast cancer: present challenges and new perspectives. Mol. Oncol., 2010;4:209-229
36. Rakha E. A., El-Sayed M. E., Green A. R., Lee A. H. S., Robertson J. F., Ellis I. O.: Prognostic markers in triple-negative breast cancer. Cancer, 2007;109:25-32
37. Rakha E. A., Elsheikh S. E., Aleskandarany M. A., Habashi H. O., Green A. R., Powe D. G., El-Sayed M. E., Benhasouna A., Brunet J. S., Akslen L. A., Evans A. J., Blamey R., Reis-Filho J. S., Foulkes W. D., Ellis I. O.: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res., 2009;15:2302-2310
38. Reddy K. B.: Triple-negative breast cancers: an updated review on treatment options. Curr. Oncol., 2011;18:e173-e179
39. Santana-Davila R., Perez E. A.: Treatment options for patients with triple-negative breast cancer. J. Hematol. Oncol., 2010;3:42
40. Stockmans G., Deraedt K., Wildiers H., Moerman P., Paridaens R.: Triple-negative breast cancer. Curr. Opin. Oncol., 2008;20:614-620
41. Tan A. R., Swain S. M.: Therapeutic strategies for triple-negative breast cancer. Cancer J., 2008;14:343-351
42. Voduc K. D., Cheang M. C., Tyldesley S., Gelmon K., Nielsen T. O., Kennecke H.: Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol., 2010;28:1684-1691
43. Whitman G. J., Albarracin C. T., Gonzalez-Angulo A. M.: Triple-negative breast cancer: what the radiologist needs to know. Semin. Roentgenol., 2011;46:26-39
44. Wojciechowska U., Didkowska J., Zatoński W.: Nowotwory zło-śliwe w Polsce w 2010 roku. Centrum Onkologii, Instytut im. M. Skłodowskiej-Curie, Warszawa 2012
45. Wojtukiewicz M. Z., Szambora P., Sierko E.: Patofizjologiczne podstawy kojarzenia leczenia anty-EGFR z chemioterapia̧. Onkol. Prakt. Klin., 2010;6:236-240
46. Wolff A. C., Hammond M. E., Schwartz J. N., Hagerty K. L., Allred D. C., Cote R. J., Dowsett M., Fitzgibbons P. L., Hanna W. M., Langer A., McShane L. M., Paik S., Pegram M. D., Perez E. A., Press M. F. i wsp.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol., 2007;25:118-145